Clinical trial results:
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID)

Summary

EudraCT number	2021-000267-72
Trial protocol	BE HU FR PL IT BG
Global end of trial date	07 April 2025

Results information

Result version number	v1 (current)
This version publication date	18 February 2026
First version publication date	18 February 2026

Trial information

Trial identification

Sponsor protocol code	D3252C00002

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	151 85, Sodertalje, Sweden,
Public contact	Global Clinical Head, AstraZeneca, +1 18772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Head, AstraZeneca, +1 18772409479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 June 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	06 August 2024
Global end of trial reached?	Yes
Global end of trial date	07 April 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the effect of benralizumab on nasal polyp burden and patient-reported nasal blockage (NB).

Protection of trial subjects:

The investigator or his/her representative explained the nature of the study to the participant or his/her legally authorised representative and answered all questions regarding the study.

Participants were informed that their participation was voluntary and they were free to refuse to participate and may withdraw their consent at any time and for any reason during the study. Participants or their legally authorised representative were required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study centre.

The medical record included a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorised person obtaining the informed consent also signed the ICF. Participants must be re-consented to the most current version of the ICF(s) during their participation in the study. A copy of the ICF(s) must be provided to the participant or the participant's legally authorised representative.

Participants who were rescreened were required to sign a new ICF.

The ICF contained a separate section that addresses and documents the collection and use of any mandatory and/or optional human biological samples. The investigator or authorized designee explained to each participant the objectives of the analysis to be done on the samples and any potential future use. Participants were told that they were free to refuse to participate in any optional samples or the future use and may withdraw their consent at any time and for any reason during the retention period.

Background therapy: -

Evidence for comparator:

After enrolment, and prior to entering a screening/run in period, eligible participants had their current daily INCS therapy standardized to Mometasone Furoate (MFNS), total daily dose of 400 mcg or equivalent (highest local approved dose for CRSwNP), which was maintained throughout the study until the last DB visit (V11).

Actual start date of recruitment	25 November 2019
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 15

Country: Number of subjects enrolled	Australia: 16
Country: Number of subjects enrolled	Belgium: 5
Country: Number of subjects enrolled	Bulgaria: 12
Country: Number of subjects enrolled	Chile: 17
Country: Number of subjects enrolled	China: 83
Country: Number of subjects enrolled	Hungary: 20
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Japan: 25
Country: Number of subjects enrolled	Poland: 28
Country: Number of subjects enrolled	Russian Federation: 6
Country: Number of subjects enrolled	Taiwan: 6
Country: Number of subjects enrolled	Thailand: 16
Country: Number of subjects enrolled	Türkiye: 9
Country: Number of subjects enrolled	United States: 13
Country: Number of subjects enrolled	Viet Nam: 2
Worldwide total number of subjects	287
EEA total number of subjects	79

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	254
From 65 to 84 years	33
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Between 15NOV2019 and 01JUN2023, a total of 295 participants were randomized to either the treatment (n=147) or placebo (n=148) arms of the double-blind treatment period. Eight participants were excluded due to Japan GCP breach. Therefore, 144 participants started in the treatment arm and 143 in the placebo arm, for a total of 287 participants.

Pre-assignment

Screening details:

All patients completed a 6-week run-in period during which inclusion/exclusion criteria was assessed, medical history and surgical history were documented, Nasal endoscopy performed, and patient reported outcomes (PROs), clinical laboratories, and diet questionnaires were administered.

Period 1

Period 1 title	Double-Blind Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Benralizumab DB

Arm description:

All participants who received Benralizumab in the double-blind (DB) period.

Arm type	Experimental
Investigational medicinal product name	30 mg Benralizumab administered every 4 weeks subcutaneously for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks (Q8W) thereafter.
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

30 mg SC

Arm title	Placebo DB

Arm description:

All participants who received Placebo in the DB period.

Arm type	Placebo
Investigational medicinal product name	30 mg Placebo administered every 4 weeks subcutaneously for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks (Q8W) thereafter.
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo SC

Number of subjects in period 1	Benralizumab DB	Placebo DB
Started	144	143
Completed	129	130
Not completed	15	13
Consent withdrawn by subject	9	6
Physician decision	1	2
Adverse event, non-fatal	1	1
Pregnancy	1	-
IP discontinuation	1	1
Lost to follow-up	-	2
Patient did not meet randomization criteria	-	1
Site closure	2	-

Period 2	
Period 2 title	Open-Label Extension Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms	
Are arms mutually exclusive?	Yes
Arm title	Benralizumab OLE

Arm description:

All participants who received Benralizumab in the double-blind (DB) period and continued to receive Benralizumab in the open-label extension (OLE) period

Arm type	Experimental
Investigational medicinal product name	30 mg Benralizumab administered every 4 weeks subcutaneously for the first 3 doses (Weeks 56, 60, 64) and Q8W thereafter (Weeks 72, 80, 88, 96 and 104).
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

30 mg SC

Arm title	Placebo switched to Benralizumab OLE

Arm description:

All participants who initially received Placebo in the DB period, then switched to receive Benralizumab in the open-label extension (OLE) period

Arm type	Experimental

Investigational medicinal product name	30 mg Benralizumab administered every 4 weeks subcutaneously for the first 3 doses (Weeks 56, 60, 64) and Q8W thereafter (Weeks 72, 80, 88, 96 and 104).
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

30 mg SC

Number of subjects in period 2[1]	Benralizumab OLE	Placebo switched to Benralizumab OLE
Started	122	125
Completed	80	86
Not completed	42	39
Consent withdrawn by subject	18	6
Physician decision	3	2
Adverse event, non-fatal	1	3
patient withdrew due to failure of treatment	1	2
Study terminated by sponsor	19	26

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: All patients who completed the 56-week double-blind treatment period were eligible to continue into one year OLE, during which all patients received 8 doses of benralizumab 30 mg. Patients who did not enter OLE, had their last study visit at Week 56 (EoDB) for follow-up and without administration of IP.

Baseline characteristics

Reporting groups	
Reporting group title	Benralizumab DB
Reporting group description:	
All participants who received Benralizumab in the double-blind (DB) period.	
Reporting group title	Placebo DB
Reporting group description:	
All participants who received Placebo in the DB period.	

Reporting group values	Benralizumab DB	Placebo DB	Total
Number of subjects	144	143	287
Age Categorical Units: Participants			
<=18 years	0	0	0
Between 18 and 65 years	128	126	254
>=65 years	16	17	33
Age Continuous Units: Years			
arithmetic mean	49.5	49.8	
standard deviation	± 12.7	± 12.7	-
Sex: Female, Male Units: Participants			
Female	61	54	115
Male	83	89	172
Race/Ethnicity, Customized Units: Subjects			
White	77	73	150
Black or African American	0	2	2
Asian	66	66	132
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Other	1	2	3

End points

End points reporting groups

Reporting group title	Benralizumab DB
Reporting group description:	
All participants who received Benralizumab in the double-blind (DB) period.	
Reporting group title	Placebo DB
Reporting group description:	
All participants who received Placebo in the DB period.	
Reporting group title	Benralizumab OLE
Reporting group description:	
All participants who received Benralizumab in the double-blind (DB) period and continued to receive Benralizumab in the open-label extension (OLE) period	
Reporting group title	Placebo switched to Benralizumab OLE
Reporting group description:	
All participants who initially received Placebo in the DB period, then switched to receive Benralizumab in the open-label extension (OLE) period	

Primary: Change from baseline in endoscopic total nasal polyp score (NPS).

End point title	Change from baseline in endoscopic total nasal polyp score (NPS).
End point description:	
The total NPS is the sum (maximum 8) of the right and left nostril scores, as evaluated by nasal endoscopy and the left and right score are based on central read with scale from 0 to 4. The total NPS and the changes from baseline to each post-baseline value was calculated.	
End point type	Primary
End point timeframe:	
Baseline to Week 56	

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	127	121		
Units: Score				
arithmetic mean (standard deviation)	-0.3 (± 1.6)	-0.1 (± 1.3)		

Statistical analyses

Statistical analysis title	Repeated measures model
Statistical analysis description:	
Null Hypothesis: Difference in mean change from baseline in NPS at 56 weeks (Benralizumab minus placebo) = 0	
Comparison groups	Benralizumab DB v Placebo DB

Number of subjects included in analysis	248
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1707
Method	ANCOVA
Parameter estimate	Difference in Least Squares Means
Point estimate	-0.247
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.599
upper limit	0.106

Primary: Change from baseline in mean nasal blockage score (NBS).

End point title	Change from baseline in mean nasal blockage score (NBS).

End point description:

The NBS is an item in the NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 – none; 1 – mild; 2 – moderate; 3 – severe. The NBS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day –13 to Day 1. Bi-weekly mean were calculated if at least 8 days in each 14-day period had evaluable data; otherwise, the biweekly mean was set to missing.

End point type	Primary

End point timeframe:

Baseline to week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	114	118		
Units: Score				
arithmetic mean (standard deviation)	-0.64 (± 0.98)	-0.45 (± 0.90)		

Statistical analyses

Statistical analysis title	Repeated measures model

Statistical analysis description:

Null Hypothesis: Difference in mean change from baseline in bi-weekly mean NBS at 56 weeks (Benralizumab minus placebo) = 0

Comparison groups	Benralizumab DB v Placebo DB

Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1831
Method	ANCOVA
Parameter estimate	Difference in Least Squares Means
Point estimate	-0.155
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.383
upper limit	0.073

Secondary: Change from baseline in difficulty with sense of smell (DSS) score

End point title	Change from baseline in difficulty with sense of smell (DSS) score

End point description:

The DSS is an item in the NPSD. Patients were asked to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0–none; 1–mild; 2–moderate; 3–severe. The DSS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day –13 to Day 1. Bi-weekly mean of DSS was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the bi-weekly mean was set to missing.

End point type	Secondary

End point timeframe:

Baseline to Week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	114	118		
Units: Score				
arithmetic mean (standard deviation)	-0.26 (± 0.78)	-0.05 (± 0.56)		

Statistical analyses

Statistical analysis title	Repeated measures model

Statistical analysis description:

Null Hypothesis: Difference in mean change from baseline in bi-weekly mean DSS at 56 weeks (Benralizumab minus placebo) = 0

Comparison groups	Benralizumab DB v Placebo DB

Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0196 [1]
Method	ANCOVA
Parameter estimate	Difference in Least Squares Means
Point estimate	-0.191
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.351
upper limit	-0.031

Notes:

[1] - The p-value is unadjusted.

Secondary: Sinus Opacification by CT Scan

End point title	Sinus Opacification by CT Scan

End point description:

Change from baseline in Lund- Mackay score (LMS). The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).

End point type	Secondary

End point timeframe:

Baseline to Week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	114	104		
Units: Score				
arithmetic mean (standard deviation)	-1.3 (± 3.4)	-0.7 (± 3.5)		

Statistical analyses

Statistical analysis title	Repeated measures model

Statistical analysis description:

Null Hypothesis: Difference in mean change from baseline in LMS at 56 weeks (Benralizumab minus placebo) = 0

Comparison groups	Benralizumab DB v Placebo DB

Number of subjects included in analysis	218
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1456
Method	ANCOVA
Parameter estimate	Difference in Least Squares Means
Point estimate	-0.663
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.559
upper limit	0.232

Secondary: Time to first nasal polyp surgery

End point title	Time to first nasal polyp surgery
End point description:	
Time to the first surgery for CRSwNP= Start date of the first surgery for CRSwNP – date of randomisation + 1	
End point type	Secondary
End point timeframe:	
Baseline to Week 56	

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	135		
Units: Months				
median (full range (min-max))	6.31 (3.3 to 10.5)	7.79 (4.4 to 12.4)		

Statistical analyses

Statistical analysis title	Proportional hazards regression model
Statistical analysis description:	
Null Hypothesis: Hazard ratio of time to first surgery for CRSwNP (Benralizumab/placebo) = 1	
Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	274
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6776 [2]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.82

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.31
upper limit	2.09

Notes:

[2] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Secondary: Disease specific health-related quality of life (HRQoL)

End point title	Disease specific health-related quality of life (HRQoL)

End point description:

Change from baseline in SinoNasal Outcome Test (SNOT-22) score. SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).

End point type	Secondary

End point timeframe:

Baseline to Week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	127	122		
Units: Score				
arithmetic mean (standard error)	-18.0 (± 29.6)	-15.2 (± 26.6)		

Statistical analyses

Statistical analysis title	Repeated measures model

Statistical analysis description:

Null Hypothesis: Difference in mean change from baseline in SNOT-22 at 56 weeks (Benralizumab minus placebo) = 0

Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	249
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5844
Method	ANCOVA
Parameter estimate	Difference in Least Squares Means
Point estimate	-1.783
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.171
upper limit	4.606

Secondary: Time to first SCS course for CRSwNP

End point title	Time to first SCS course for CRSwNP

End point description:

Time to the first SCS use for CRSwNP = Start date of the first SCS use for CRSwNP – date of randomisation + 1

End point type	Secondary

End point timeframe:

Baseline to Week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	135		
Units: Months				
median (full range (min-max))	5.62 (0.1 to 13.0)	6.37 (0.1 to 11.4)		

Statistical analyses

Statistical analysis title	Proportional hazards regression model

Statistical analysis description:

Null Hypothesis: Hazard ratio of time to first SCS use for CRSwNP (Benralizumab/placebo) = 1

Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	274
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.8033 [3]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.69

Notes:

[3] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Secondary: Time to first NP surgery and/or SCS use for CRSwNP

End point title	Time to first NP surgery and/or SCS use for CRSwNP

End point description:

Time to first surgery and/or SCS use for CRSwNP = earlier date of (start date of first surgery for CRSwNP, start date of first SCS use for CRSwNP) – date of randomisation + 1

End point type	Secondary
End point timeframe:	
Baseline to Week 56	

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	135		
Units: Months				
median (full range (min-max))	5.70 (0.1 to 13.0)	6.37 (0.1 to 12.4)		

Statistical analyses

Statistical analysis title	Proportional hazards regression model
Statistical analysis description:	
Null Hypothesis: Hazard ratio of time to first surgery and/or SCS use for CRSwNP (Benralizumab/placebo) = 1	
Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	274
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5226 [4]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.43

Notes:

[4] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Secondary: Change from baseline in bi-weekly mean nasal polyps symptom diary total symptom score

End point title	Change from baseline in bi-weekly mean nasal polyps symptom diary total symptom score
End point description:	
Patients were asked to consider their experience with NP over the past 24 hours when responding to each question and report the severity of each symptom at its worst using a 4-point rating scale (0–none; 1–mild; 2–moderate; 3–severe). Questions to capture patient-reported difficulty with sleep and daily activities due to nasal symptoms use the same rating scale. A TSS (total symptom score) was calculated by taking the sum of the first 8 items in the NPSD (Nasal polyps symptom diary). Bi-weekly mean of each item in the NPSD was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the biweekly mean was set to missing.	
End point type	Secondary
End point timeframe:	
Baseline to Week 56	

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	114	118		
Units: Score				
arithmetic mean (standard deviation)	-3.19 (± 5.78)	-2.32 (± 5.83)		

Statistical analyses

Statistical analysis title	Repeated measures model
Statistical analysis description:	
Null Hypothesis: Difference in mean change from baseline in NPSD TSS at 56 weeks (Benralizumab minus placebo) = 0	
Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2201 [5]
Method	ANCOVA
Parameter estimate	Difference in Least Squares Means
Point estimate	-0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.235
upper limit	0.515

Notes:

[5] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Secondary: Proportion of patients with surgery for CRSwNP

End point title	Proportion of patients with surgery for CRSwNP
End point description:	
Proportion of patients with surgery for CRSwNP	
End point type	Secondary
End point timeframe:	
Baseline to Week 56	

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	135		
Units: Participants	8	10		

Statistical analyses

Statistical analysis title	Cochran–Mantel–Haenszel (CMH) test

Statistical analysis description:

Cochran–Mantel–Haenszel (CMH) test stratified by region, and baseline BMI status.

Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	274
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5662 [6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.28
upper limit	1.99

Notes:

[6] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Secondary: Proportion of patients with surgery and/or use SCS for CRSwNP

End point title	Proportion of patients with surgery and/or use SCS for CRSwNP

End point description:

The number of courses of SCS for CRSwNP: noted an SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course > 7)

End point type	Secondary

End point timeframe:

Baseline to Week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	135		
Units: Participants	26	30		

Statistical analyses

Statistical analysis title	Cochran–Mantel–Haenszel (CMH) test

Statistical analysis description:

Cochran–Mantel–Haenszel (CMH) test stratified by region, and baseline BMI status.

Comparison groups	Benralizumab DB v Placebo DB
Number of subjects included in analysis	274
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.513 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.45
upper limit	1.48

Notes:

[7] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Secondary: Proportion of patients with SCS use for CRSwNP

End point title	Proportion of patients with SCS use for CRSwNP

End point description:

The number of courses of SCS for CRSwNP: noted an SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course > 7)

End point type	Secondary

End point timeframe:

Baseline to Week 56

End point values	Benralizumab DB	Placebo DB		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	135		
Units: Participants	21	22		

Statistical analyses

Statistical analysis title	Cochran–Mantel–Haenszel (CMH) test

Statistical analysis description:

Cochran–Mantel–Haenszel (CMH) test stratified by region, and baseline BMI status.

Comparison groups	Benralizumab DB v Placebo DB

Number of subjects included in analysis	274
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8454 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.81

Notes:

[8] - This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

On study AEs were collected from the first dose to the last date in study, up to 112 weeks.

Adverse event reporting additional description:

AEs during DB period: date of first dose of IP in DB period ≤ AE onset date ≤ EoDB, except any AE that started on or after the date of first OLE dose was counted in the OLE and not in the DB period.
• AEs during the OLE period: date of first dose of IP in OLE ≤ AE onset date ≤ study completion or withdrawal date.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	27.0

Reporting groups

Reporting group title	Benralizumab DB

Reporting group description:

All participants who received Benralizumab in the double-blind (DB) period.

Reporting group title	Placebo switched to Benralizumab OLE

Reporting group description:

All participants who initially received Placebo in the DB period, then switched to receive Benralizumab in the open-label extension (OLE) period

Reporting group title	Benralizumab OLE

Reporting group description:

All participants who received Benralizumab in the double-blind (DB) period and continued to receive Benralizumab in the open-label extension (OLE) period

Reporting group title	Placebo DB

Reporting group description:

All participants who received Placebo in the DB period.

Serious adverse events	Benralizumab DB	Placebo switched to Benralizumab OLE	Benralizumab OLE
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 144 (8.33%)	9 / 125 (7.20%)	6 / 122 (4.92%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colorectal adenoma			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			

subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	1 / 122 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cancer			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fibula fracture			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	1 / 122 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Guillain-Barre syndrome			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Reflux gastritis			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic gastritis			

subjects affected / exposed	1 / 144 (0.69%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval leukoplakia			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthmatic crisis			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic rhinosinusitis with nasal polyps			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	1 / 122 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus urinary			

subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	2 / 122 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	1 / 144 (0.69%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Lower respiratory tract infection			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	1 / 122 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 144 (0.00%)	0 / 125 (0.00%)	1 / 122 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of asthma			
subjects affected / exposed	0 / 144 (0.00%)	1 / 125 (0.80%)	0 / 122 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo DB		
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 143 (8.39%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colorectal adenoma			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Invasive breast carcinoma			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transitional cell carcinoma			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Prostate cancer			

subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Papillary thyroid cancer			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fibula fracture			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meniscus injury			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Guillain-Barre syndrome			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest discomfort			

subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Cataract			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Reflux gastritis			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoids			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic gastritis			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast			

disorders			
Adenomyosis			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vulval leukoplakia			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthmatic crisis			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthma			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic rhinosinusitis with nasal polyps			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			

subjects affected / exposed	0 / 143 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
COVID-19				
subjects affected / exposed	0 / 143 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19 pneumonia				
subjects affected / exposed	0 / 143 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia bacterial				
subjects affected / exposed	0 / 143 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	2 / 143 (1.40%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Otitis media				
subjects affected / exposed	1 / 143 (0.70%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	1 / 143 (0.70%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 143 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infective exacerbation of asthma				

subjects affected / exposed	0 / 143 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Benralizumab DB	Placebo switched to Benralizumab OLE	Benralizumab OLE
Total subjects affected by non-serious adverse events			
subjects affected / exposed	78 / 144 (54.17%)	33 / 125 (26.40%)	37 / 122 (30.33%)
Nervous system disorders			
Headache			
subjects affected / exposed	11 / 144 (7.64%)	4 / 125 (3.20%)	1 / 122 (0.82%)
occurrences (all)	15	9	1
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	7 / 144 (4.86%)	0 / 125 (0.00%)	2 / 122 (1.64%)
occurrences (all)	8	0	2
Pyrexia			
subjects affected / exposed	7 / 144 (4.86%)	4 / 125 (3.20%)	1 / 122 (0.82%)
occurrences (all)	7	5	1
Gastrointestinal disorders			
Chronic gastritis			
subjects affected / exposed	6 / 144 (4.17%)	2 / 125 (1.60%)	0 / 122 (0.00%)
occurrences (all)	7	2	0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	16 / 144 (11.11%)	8 / 125 (6.40%)	7 / 122 (5.74%)
occurrences (all)	20	10	8
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 144 (1.39%)	3 / 125 (2.40%)	2 / 122 (1.64%)
occurrences (all)	2	3	2
Back pain			
subjects affected / exposed	7 / 144 (4.86%)	2 / 125 (1.60%)	1 / 122 (0.82%)
occurrences (all)	7	2	1

Infections and infestations			
COVID-19			
subjects affected / exposed	22 / 144 (15.28%)	7 / 125 (5.60%)	9 / 122 (7.38%)
occurrences (all)	23	7	9
Influenza			
subjects affected / exposed	1 / 144 (0.69%)	1 / 125 (0.80%)	4 / 122 (3.28%)
occurrences (all)	1	1	4
Nasopharyngitis			
subjects affected / exposed	11 / 144 (7.64%)	8 / 125 (6.40%)	9 / 122 (7.38%)
occurrences (all)	12	9	10
Pneumonia			
subjects affected / exposed	3 / 144 (2.08%)	4 / 125 (3.20%)	1 / 122 (0.82%)
occurrences (all)	3	4	1
Upper respiratory tract infection			
subjects affected / exposed	13 / 144 (9.03%)	4 / 125 (3.20%)	9 / 122 (7.38%)
occurrences (all)	16	5	10

Non-serious adverse events	Placebo DB		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	59 / 143 (41.26%)		
Nervous system disorders			
Headache			
subjects affected / exposed	7 / 143 (4.90%)		
occurrences (all)	10		
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	4 / 143 (2.80%)		
occurrences (all)	6		
Pyrexia			
subjects affected / exposed	3 / 143 (2.10%)		
occurrences (all)	3		
Gastrointestinal disorders			
Chronic gastritis			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			

Asthma			
subjects affected / exposed	22 / 143 (15.38%)		
occurrences (all)	31		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 143 (4.20%)		
occurrences (all)	6		
Back pain			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences (all)	1		
Infections and infestations			
COVID-19			
subjects affected / exposed	16 / 143 (11.19%)		
occurrences (all)	16		
Influenza			
subjects affected / exposed	3 / 143 (2.10%)		
occurrences (all)	3		
Nasopharyngitis			
subjects affected / exposed	9 / 143 (6.29%)		
occurrences (all)	10		
Pneumonia			
subjects affected / exposed	1 / 143 (0.70%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	14 / 143 (9.79%)		
occurrences (all)	18		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 September 2020	Added study mitigation language which provided sites with measures that may be implemented if a participant was not able to visit a study site to ensure that the clinical trial can continue whilst minimizing risk to the participant, maintaining compliance with GCP, and minimizing risks to the study integrity.
12 February 2021	Augmenting the eligibility criteria to enroll a population who will be benefit from Benralizumab; providing the eligible patients with additional around one-year treatment with open-label benralizumab; adding intranasal corticosteroid spray (INCS) as background treatment which is align with global standard of care for nasal polyps; increasing the sample size since western cohort has been included. The list of key secondary endpoints was updated.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported